356.32 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||335.00 x 900|
|Ask||359.59 x 800|
|Day's Range||350.98 - 356.51|
|52 Week Range||196.00 - 357.93|
|PE Ratio (TTM)||81.02|
|Earnings Date||Oct 22, 2018 - Oct 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||343.07|
We rank 40 of the Bay Area's biggest tech employers by how much they pay a median worker, and find that the highest-paying isn't a behemoth like Google, Salesforce.com or Intel Corp. It's not even Facebook, although the typical worker at the Menlo Park social media giant takes home a whopping $240,430 annual salary.
In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.
Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues. It is characterized by a high volume of relatively low-dollar transactions. Under DIS, Quest provides clinical testing and other services. Major customer groups for DIS include healthcare insurers, government payers, client payers, and patients.
Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.
Hologic (HOLX) is a medical technology company focused on women’s health with headquarters in Marlborough, Massachusetts. The company offers solutions across four segments including diagnostics, breast and skeletal health, gynecological surgery, and medical aesthetics. The company recently provided an update on the financial impact of its recently announced marketing and distribution suspension of its TempSure Vitalia handpiece and probes. We discussed the details in the previous article of this series. ...
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.
Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.
One is a pioneer in liquid biopsies that already has tests on the market to uncover cancer; the other is a small company that only recently started its first clinical trial.
Assessing Illumina Inc’s (NASDAQ:ILMN) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, whichRead More...
Hologic (HOLX) is a medical technology firm focused on improving women’s health. The company operates across four segments: diagnostics, GYN surgical, breast cancer, and skeletal health. The company reported strong Q3 2018 earnings results, which led to a rise in its stock price. In this article, let’s look at analysts’ recommendations for HOLX stock.
PerkinElmer is working to ease the drug discovery process for pharmaceutical companies with its suite of research, detection and diagnostics tools.
MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.
BOULDER, Colo., Sept. 5, 2018 /PRNewswire/ -- Inscripta™, a leading gene-editing technology company, today announced the strategic acquisition of Solana Biosciences, a life sciences company founded by Illumina™ (ILMN) veterans. Through the acquisition, Inscripta and Solana have joined forces to accelerate the commercialization of Inscripta's suite of gene-editing technology tools. Inscripta's acquisition of Solana assembles an elite, life-sciences product development and manufacturing pipeline for precision gene editing.
Illumina (ILMN) reached its 52-week high of $357.93 per share on August 31. On August 28, Illumina’s MiSeqDx sequencing system received approval in China. On August 16, ILMN stock fell ~2.1% in after-hours trading due to the news of the company’s plans to offer $650 million of convertible senior notes, which will be due by 2023.
Wall Street???s robust performance in August was fueled by strong second-quarter 2018 earnings results and solid macro-economic data like GDP, retail sales, consumer confidence and job data.